Inhibition of Poly(ADP-Ribose) Polymerase Enhances the Effect of Chemotherapy in an Animal Model of Regional Therapy for the Treatment of Advanced Extremity Malignant Melanoma-Reference-Cited by-同舟云学术

Inhibition of Poly(ADP-Ribose) Polymerase Enhances the Effect of Chemotherapy in an Animal Model of Regional Therapy for the Treatment of Advanced Extremity Malignant Melanoma

Published:2010-02-24 Issue:8 Volume:17 Page:2247-2254
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Toshimitsu Hiroaki,Yoshimoto Yasunori,Augustine Christina K.,Padussis James C.,Yoo Jin S.,Angelica Selim M.,Pruitt Scott K.,Friedman Henry S.,Ali-Osman Francis,Tyler Douglas S.

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

http://link.springer.com/content/pdf/10.1245/s10434-010-0971-x.pdf

Reference29 articles.

1. Augustine CK, Yoo JS, Potti A, Yoshimoto Y, Zipfel PA, Friedman HS, et al. Genomic and molecular profiling predicts response to temozolomide in melanoma. Clin Cancer Res. 2009;15:502–10.

2. Bignami M, O’Driscoll M, Aquilina G, Karran P. Unmasking a killer: DNA O(6)-methylguanine and the cytotoxicity of methylating agents. Mutat Res. 2000;462:71–82.

3. Tentori L, Portarena I, Graziani G. Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors. Pharmacol Res. 2002;45:73–85.

4. Virag L, Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev. 2002;54:375–429.

5. Sarkaria JN, Kitange GJ, James CD, Plummer R, Calvert H, Weller M, et al. Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res. 2008;14:2900–8.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Critical appraisal of MGMT in digestive NET treated with alkylating agents;Endocrine-Related Cancer;2020-10

2. Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities;Medicinal Research Reviews;2017-05-16

3. PARP inhibitors as antitumor agents: a patent update (2013-2015);Expert Opinion on Therapeutic Patents;2016-11-21

4. Temozolomide-based combination for advanced neuroendocrine neoplasms: a systematic review of the literature;Future Oncology;2015-04

5. PARP inhibitor attenuated colony formation can be restored by MAP kinase inhibitors in different irradiated cancer cell lines;International Journal of Radiation Biology;2014-11-14